• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.

作者信息

Mullanfiroze Khushnuma, Lazareva Arina, Chu Jan, Williams Lindsey, Burridge Saskia, Silva Juliana, Chiesa Robert, Rao Kanchan, Lucchini Giovanna, Ghorashian Sara, O'Reilly Maeve, Carpenter Ben, Grandage Victoria, Hough Rachael, Roddie Claire, Amrolia Persis J

机构信息

Department of Blood and Marrow Transplant, and.

Department of Haematology, Great Ormond Street Hospital, London, United Kingdom; and.

出版信息

Blood Adv. 2022 Aug 23;6(16):4715-4718. doi: 10.1182/bloodadvances.2022007572.

DOI:10.1182/bloodadvances.2022007572
PMID:35790110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631677/
Abstract
摘要

相似文献

1
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.选择CD34+干细胞增强疗法可安全改善CAR T细胞治疗后的血细胞减少症。
Blood Adv. 2022 Aug 23;6(16):4715-4718. doi: 10.1182/bloodadvances.2022007572.
2
Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy.异基因 CD34 选择的干细胞增强作为 CAR-T 细胞治疗后危及生命的感染和严重细胞减少症的挽救治疗。
Transfusion. 2022 Oct;62(10):2143-2147. doi: 10.1111/trf.17071. Epub 2022 Aug 20.
3
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.干细胞增强疗法作为CD19嵌合抗原受体T细胞疗法后严重血液毒性挽救治疗的安全性和可行性。
Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776.
4
CD34 selected alloPBSCT and adoptive immunotherapy.CD34 选择的异基因外周血干细胞移植及过继性免疫治疗
Bone Marrow Transplant. 2000 May;25 Suppl 2:S2-5. doi: 10.1038/sj.bmt.1702342.
5
Fresh or Cryopreserved CD34-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.新鲜或冷冻保存的CD34选择的动员外周血干细胞和祖细胞用于治疗异基因造血细胞移植后的移植物功能不良
Biol Blood Marrow Transplant. 2017 Jul;23(7):1072-1077. doi: 10.1016/j.bbmt.2017.03.019. Epub 2017 Mar 18.
6
Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.表达基于配体的嵌合抗原受体靶向CD116的T细胞对幼年型粒单核细胞白血病CD34(+)细胞的抗增殖作用
J Hematol Oncol. 2016 Mar 16;9:27. doi: 10.1186/s13045-016-0256-3.
7
CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.CD34(+)选择的干细胞增强疗法用于异基因干细胞移植后植入延迟或植入不足的情况。
Cytotherapy. 2006;8(4):375-80. doi: 10.1080/14653240600735784.
8
Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.在异基因非亲缘匹配或不匹配造血细胞移植后，通过CD34+选择的干细胞增强可持久且安全地改善移植功能不佳的情况。
J Cancer Res Clin Oncol. 2015 Dec;141(12):2241-51. doi: 10.1007/s00432-015-2027-x. Epub 2015 Aug 14.
9
CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease.CD34选择的干细胞增强疗法用于镰状细胞病异基因移植后晚期移植物排斥反应的治疗。
Bone Marrow Transplant. 2022 Oct;57(10):1592-1594. doi: 10.1038/s41409-022-01749-9. Epub 2022 Jul 7.
10
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.CD34 选择的异基因造血干细胞移植治疗复发高危多发性骨髓瘤患者
Biol Blood Marrow Transplant. 2016 Feb;22(2):258-267. doi: 10.1016/j.bbmt.2015.08.025. Epub 2015 Aug 30.

引用本文的文献

1
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
2
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.免疫效应细胞相关的血液毒性：机制、临床表现及管理策略。
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
3
Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.供体CLL-1嵌合抗原受体T细胞在异基因造血干细胞移植后复发急性髓系白血病治疗中的应用。
Front Immunol. 2025 Jan 17;15:1491341. doi: 10.3389/fimmu.2024.1491341. eCollection 2024.
4
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.嵌合抗原受体T细胞（CAR-T细胞）治疗T细胞急性淋巴细胞白血病/淋巴瘤的临床疗效与安全性
Ann Hematol. 2025 Jan;104(1):57-63. doi: 10.1007/s00277-024-06132-w. Epub 2024 Dec 18.
5
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.早期免疫效应细胞相关血液毒性预测模型的开发与验证
Blood Adv. 2025 Feb 11;9(3):606-616. doi: 10.1182/bloodadvances.2024014455.
6
Successful allogeneic CD34 hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).成功进行异基因CD34造血干细胞增强治疗，用于治疗B细胞急性淋巴细胞白血病患者接受CAR T细胞治疗后出现的长期血细胞减少症。西班牙造血移植与细胞治疗小组（GETH-TC）代表发言。
Bone Marrow Transplant. 2025 Feb;60(2):250-253. doi: 10.1038/s41409-024-02473-2. Epub 2024 Nov 17.
7
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.嵌合抗原受体T细胞血液学毒性的新见解：表现、机制及有效管理策略
Exp Hematol Oncol. 2024 Nov 9;13(1):110. doi: 10.1186/s40164-024-00573-9.
8
Optimal infused CD34 cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.多发性骨髓瘤患者行 upfront 自体造血干细胞移植时的最优输注 CD34 细胞剂量。
Blood Cancer J. 2024 Oct 31;14(1):189. doi: 10.1038/s41408-024-01165-w.
9
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.抗CD19嵌合抗原受体T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤后的晚期事件
Front Oncol. 2024 Jun 11;14:1404351. doi: 10.3389/fonc.2024.1404351. eCollection 2024.
10
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations.嵌合抗原受体 T 细胞毒性：从床边到实验室，新型毒性如何为实验室研究提供信息。
Blood Adv. 2024 Aug 27;8(16):4348-4358. doi: 10.1182/bloodadvances.2024013044.

本文引用的文献

1
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.严重细胞因子释放综合征与 CD19 CAR T 细胞治疗后的血液学毒性有关。
Blood Adv. 2022 Apr 12;6(7):2055-2068. doi: 10.1182/bloodadvances.2020004142.
2
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.异基因造血干细胞移植后 CD34 选择干细胞增强治疗移植物功能不良的结局：系统评价和荟萃分析。
Transplant Cell Ther. 2021 Oct;27(10):877.e1-877.e8. doi: 10.1016/j.jtct.2021.07.012. Epub 2021 Jul 18.
3
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
4
Hematologic Rescue of CAR T-cell-mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient.淋巴瘤患者中使用自体外周血造血干细胞对CAR T细胞介导的长期全血细胞减少进行血液学挽救
Hemasphere. 2021 Feb 17;5(3):e545. doi: 10.1097/HS9.0000000000000545. eCollection 2021 Mar.
5
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.CD19 靶向 CAR T 细胞治疗后骨髓衰竭导致严重光滑念珠菌全结肠炎和致命烟曲霉肺部感染 - 一例报告。
BMC Infect Dis. 2021 Jan 28;21(1):121. doi: 10.1186/s12879-020-05755-4.
6
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.接受嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤患者的造血恢复情况。
Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.
7
Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells.通过输注冷冻保存的干细胞成功治疗骨髓瘤CAR T细胞疗法后的骨髓衰竭。
Am J Hematol. 2020 Jan;95(1):E20-E23. doi: 10.1002/ajh.25664. Epub 2019 Nov 9.
8
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.低亲和力 CD19 CAR 治疗儿童 ALL 患者可增强 CAR T 细胞扩增和延长持久性。
Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2.
9
Early and late hematologic toxicity following CD19 CAR-T cells.CD19嵌合抗原受体T细胞治疗后的早期和晚期血液学毒性
Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.
10
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.